703 related articles for article (PubMed ID: 28488168)
1. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
2. Assessing the relationship between tumor-infiltrating lymphocytes and PD-L1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting.
Suwannaphoom K; Soontornsit S; Wiwatwarayos K; Seneetuntigul P; Julimasart P
Ann Diagn Pathol; 2024 Jun; 70():152294. PubMed ID: 38513466
[TBL] [Abstract][Full Text] [Related]
3. TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.
Dadiani M; Necula D; Kahana-Edwin S; Oren N; Baram T; Marin I; Morzaev-Sulzbach D; Pavlovski A; Balint-Lahat N; Anafi L; Wiemann S; Korner C; Gal-Yam EN; Avivi C; Kaufman B; Barshack I; Ben-Baruch A
Cancer Immunol Immunother; 2020 Jul; 69(7):1315-1326. PubMed ID: 32198536
[TBL] [Abstract][Full Text] [Related]
4. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Gonzalez-Ericsson PI; Stovgaard ES; Sua LF; Reisenbichler E; Kos Z; Carter JM; Michiels S; Le Quesne J; Nielsen TO; Laenkholm AV; Fox SB; Adam J; Bartlett JM; Rimm DL; Quinn C; Peeters D; Dieci MV; Vincent-Salomon A; Cree I; Hida AI; Balko JM; Haynes HR; Frahm I; Acosta-Haab G; Balancin M; Bellolio E; Yang W; Kirtani P; Sugie T; Ehinger A; Castaneda CA; Kok M; McArthur H; Siziopikou K; Badve S; Fineberg S; Gown A; Viale G; Schnitt SJ; Pruneri G; Penault-Llorca F; Hewitt S; Thompson EA; Allison KH; Symmans WF; Bellizzi AM; Brogi E; Moore DA; Larsimont D; Dillon DA; Lazar A; Lien H; Goetz MP; Broeckx G; El Bairi K; Harbeck N; Cimino-Mathews A; Sotiriou C; Adams S; Liu SW; Loibl S; Chen IC; Lakhani SR; Juco JW; Denkert C; Blackley EF; Demaria S; Leon-Ferre R; Gluz O; Zardavas D; Emancipator K; Ely S; Loi S; Salgado R; Sanders M;
J Pathol; 2020 Apr; 250(5):667-684. PubMed ID: 32129476
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer.
Lee H; Kim YA; Kim Y; Park HS; Seo JH; Lee H; Gong G; Lee HJ
Cancer Immunol Immunother; 2020 Nov; 69(11):2381-2391. PubMed ID: 32529292
[TBL] [Abstract][Full Text] [Related]
6. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ
J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of PD-L1 expression and intratumoral lymphocytic infiltration in triple-negative invasive breast carcinoma].
Barrios Barreto R; Silvera Redondo C; Garavito MDP; Ardila Pereira L
Medicina (B Aires); 2024; 84(2):227-235. PubMed ID: 38683507
[TBL] [Abstract][Full Text] [Related]
9. Multiplexed immunofluorescence identifies high stromal CD68
Wang J; Browne L; Slapetova I; Shang F; Lee K; Lynch J; Beretov J; Whan R; Graham PH; Millar EKA
Sci Rep; 2021 Nov; 11(1):21608. PubMed ID: 34732817
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.
Singh L; Singh MK; Kenney MC; Jager MJ; Rizvi MA; Meel R; Lomi N; Bakhshi S; Sen S; Kashyap S
Cancer Immunol Immunother; 2021 May; 70(5):1291-1303. PubMed ID: 33136179
[TBL] [Abstract][Full Text] [Related]
11. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ
Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809
[TBL] [Abstract][Full Text] [Related]
12. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Dirix LY; Takacs I; Jerusalem G; Nikolinakos P; Arkenau HT; Forero-Torres A; Boccia R; Lippman ME; Somer R; Smakal M; Emens LA; Hrinczenko B; Edenfield W; Gurtler J; von Heydebreck A; Grote HJ; Chin K; Hamilton EP
Breast Cancer Res Treat; 2018 Feb; 167(3):671-686. PubMed ID: 29063313
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer.
Čeprnja T; Tomić S; Perić Balja M; Marušić Z; Blažićević V; Spagnoli GC; Juretić A; Čapkun V; Vuger AT; Pogorelić Z; Mrklić I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674098
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study.
Wahba MG; Soliman SS; Salama ME; Nasr S; Al Shereef ZAE
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1441-1450. PubMed ID: 38680006
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.
Sun GY; Zhang J; Wang BZ; Jing H; Fang H; Tang Y; Song YW; Jin J; Liu YP; Tang Y; Qi SN; Chen B; Lu NN; Li N; Li YX; Ying JM; Wang SL
Br J Cancer; 2023 Jun; 128(11):2044-2053. PubMed ID: 36966236
[TBL] [Abstract][Full Text] [Related]
16. A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
Orth MF; Buecklein VL; Kampmann E; Subklewe M; Noessner E; Cidre-Aranaz F; Romero-Pérez L; Wehweck FS; Lindner L; Issels R; Kirchner T; Altendorf-Hofmann A; Grünewald TGP; Knösel T
Cancer Immunol Immunother; 2020 Jul; 69(7):1353-1362. PubMed ID: 32222780
[TBL] [Abstract][Full Text] [Related]
17. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
[TBL] [Abstract][Full Text] [Related]
18. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients.
Omura Y; Toiyama Y; Okugawa Y; Yin C; Shigemori T; Kusunoki K; Kusunoki Y; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Ohi M; Kusunoki M
Cancer Immunol Immunother; 2020 Dec; 69(12):2533-2546. PubMed ID: 32577816
[TBL] [Abstract][Full Text] [Related]
20. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
